Orphazyme A/S
Arimoclomol formulation
Last updated:
Abstract:
The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.
Status:
Grant
Type:
Utility
Filling date:
23 Mar 2020
Issue date:
25 Jan 2022